CARDIAC-TAMPONADE EARLY AFTER THROMBOLYSIS FOR ACUTE MYOCARDIAL-INFARCTION - A RARE BUT NOT REPORTED HEMORRHAGIC COMPLICATION

被引:31
作者
RENKIN, J [1 ]
DEBRUYNE, B [1 ]
BENIT, E [1 ]
JORIS, JM [1 ]
CARLIER, M [1 ]
COL, J [1 ]
机构
[1] CATHOLIC UNIV LOUVAIN, SCH MED, DEPT INTENS CARE, CORONARY CARE UNIT, B-1200 BRUSSELS, BELGIUM
关键词
D O I
10.1016/0735-1097(91)90739-V
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Among 392 consecutive patients admitted for acute myocardial infarction and treated with thrombolytic drugs, 4 patients (1%) developed an early hemorrhagic pericardial effusion (without ventricular wall rupture) evolving within 24 h to cardiogenic shock consequent to cardiac tamponade. They all suffered from a large anterior myocardial infarction treated within 4 h after onset of symptoms with intravenous anisoylated plasminogen streptokinase activator complex (one case), recombinant tissue-type plasminogen activator (rt-PA) (two cases) or streptokinase (one case), antiocagulation with heparin (all cases) and aspirin (three cases) As soon as pericardial effusion was established by echocardiography, emergency percutaneous pericardiocentesis was performed at the bedside 20 +/- 6 h after thrombolytic therapy was started. This corrected immediately the clinical and hemodynamic status of each patient and a catheter was left in the pericardial space for 34 +/- 18 h. Thus, in the presence of unexplained clinical and hemodynamic deterioration occurring during the first 24 h after thrombolytic treatment of a large myocardial infarction, cardiac tamponade should be suspected. Immediate percutaneous pericardiocentesis followed by continuous drainage is a simple and definitive treatment for this complication.
引用
收藏
页码:280 / 285
页数:6
相关论文
共 29 条
[1]  
[Anonymous], 1988, LANCET, V2, P349
[2]  
[Anonymous], 1986, Lancet, V1, P397
[3]   MULTICENTER TRIAL OF INTRAVENOUS ANISOYLATED PLASMINOGEN STREPTOKINASE ACTIVATOR COMPLEX (APSAC) IN ACUTE MYOCARDIAL-INFARCTION - EFFECTS ON INFARCT SIZE AND LEFT-VENTRICULAR FUNCTION [J].
BASSAND, JP ;
MACHECOURT, J ;
CASSAGNES, J ;
ANGUENOT, T ;
LUSSON, R ;
BOREL, E ;
PEYCELON, P ;
WOLF, E ;
DUCELLIER, D .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1989, 13 (05) :988-997
[5]   HEMORRHAGIC COMPLICATIONS ASSOCIATED WITH THE USE OF INTRAVENOUS TISSUE PLASMINOGEN-ACTIVATOR IN TREATMENT OF ACUTE MYOCARDIAL-INFARCTION [J].
CALIFF, RM ;
TOPOL, EJ ;
GEORGE, BS ;
BOSWICK, JM ;
ABBOTTSMITH, C ;
SIGMON, KN ;
CANDELA, R ;
MASEK, R ;
KEREIAKES, D ;
ONEILL, WW ;
STACK, RS ;
STUMP, D .
AMERICAN JOURNAL OF MEDICINE, 1988, 85 (03) :353-359
[6]  
CHAMBERLAIN DA, 1988, LANCET, V1, P545
[7]   PHARMACOKINETICS, THROMBOLYTIC EFFICACY AND HEMORRHAGIC RISK OF DIFFERENT STREPTOKINASE REGIMENS IN HEPARIN-TREATED ACUTE MYOCARDIAL-INFARCTION [J].
COL, JJ ;
COLDEBEYS, CM ;
RENKIN, JP ;
LAVENNEPARDONGE, EM ;
BACHY, JL ;
MORIAU, MH .
AMERICAN JOURNAL OF CARDIOLOGY, 1989, 63 (17) :1185-1192
[8]   HEMODYNAMIC-EFFECT OF DEXTRAN, DOBUTAMINE, AND PERICARDIOCENTESIS IN CARDIAC-TAMPONADE SECONDARY TO SUBACUTE HEART RUPTURE [J].
COMACANELLA, I ;
LOPEZSENDON, J ;
GARCIA, AG ;
JADRAQUE, LM .
AMERICAN HEART JOURNAL, 1987, 114 (01) :78-84
[9]   SUBACUTE LEFT-VENTRICULAR FREE WALL RUPTURE FOLLOWING ACUTE MYOCARDIAL-INFARCTION - BEDSIDE HEMODYNAMICS, DIFFERENTIAL-DIAGNOSIS, AND TREATMENT [J].
COMACANELLA, I ;
LOPEZSENDON, J ;
GONZALEZ, LN ;
FERRUFINO, O .
AMERICAN HEART JOURNAL, 1983, 106 (02) :278-284
[10]   A CLINICOPATHOLOGICAL STUDY OF PATIENTS WITH HEMORRHAGIC MYOCARDIAL-INFARCTION TREATED WITH SELECTIVE CORONARY THROMBOLYSIS WITH UROKINASE [J].
FUJIWARA, H ;
ONODERA, T ;
TANAKA, M ;
FUJIWARA, T ;
WU, DJ ;
KAWAI, C ;
HAMASHIMA, Y .
CIRCULATION, 1986, 73 (04) :749-757